Over a month ago
Conference/Events
2020 Wells Fargo Biotech…
2020 Wells Fargo Biotech Virtual Corporate Access Day will be held on April 7. Webcast Link
Show Hide Related Items >> <<
10/23/19 Adaptimmune management to meet with SunTrust 08/02/19 Fly Intel: Top five analyst downgrades 08/02/19 Guggenheim Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim 08/01/19 Guggenheim Adaptimmune downgraded to Neutral from Buy at Guggenheim 01/22/20 Stifel Akcea LICA data look 'solid,' as expected, says Stifel 10/08/19 BMO Capital Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital 10/07/19 Stifel Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel 10/07/19 Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo 02/12/20 Roth Capital Applied Genetic in position to execute after cash raise, says Roth Capital 01/28/20 Fly Intel: Top five analyst initiations 01/27/20 Roth Capital Applied Genetic initiated with a Buy at Roth Capital 01/09/20 BMO Capital Applied Genetic price target raised to $16 from $9 at BMO Capital ARNA Arena Pharmaceuticals 03/31/20 Guggenheim Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod 03/31/20 Guggenheim Arena Pharmaceuticals initiated with a Buy at Guggenheim 03/26/20 BofA Arena Pharmaceuticals upgraded to Buy on recent selloff at BofA 03/26/20 BofA Arena Pharmaceuticals upgraded to Buy from Neutral at BofA AUTL Autolus Therapeutics 02/18/20 H.C. Wainwright Now the time to get long Autolus Therapeutics, says H.C. Wainwright 09/23/19 Needham Autolus Therapeutics initiated with a Buy at Needham 09/23/19 Needham Autolus Therapeutics initiated with a Buy at Needham 09/12/19 H.C. Wainwright Autolus' Woodford overhang in the rearview, says H.C. Wainwright 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright 03/17/20 Janney Montgomery Scott Avrobio weakness a buying opportunity, says Janney Montgomery Scott 02/19/20 Nomura Instinet Avrobio price target raised to $50 from $35 at Nomura Instinet 02/11/20 Mizuho Avrobio price target raised to $35 from $28 at Mizuho 03/27/20 BMO Capital Bluebird Bio price target lowered to $107 from $132 at BMO Capital 03/26/20 Bluebird Bio upgraded to Buy from Hold at Stifel 03/26/20 Stifel Bluebird Bio upgraded to Buy from Hold at Stifel 03/26/20 Piper Sandler Bluebird Bio price target lowered to $75 from $85 at Piper Sandler 03/26/20 Wells Fargo Celyad price target lowered to $20 from $44 at Wells Fargo 03/25/20 H.C. Wainwright Celyad price target lowered to $37 from $43 at H.C. Wainwright 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 04/01/20 Piper Sandler Crispr Therapeutics study halts not unexpected, says Piper Sandler 03/04/20 Stifel Crispr Therapeutics initiated with a Hold at Stifel 02/13/20 Piper Sandler Crispr Therapeutics ended year with $943M in cash, says Piper Sandler 02/03/20 Evercore ISI Evercore ISI downgrades Crispr Therapeutics, questions relative valuation 07/26/19 Fly Intel: Top five analyst initiations 07/25/19 Baird Gritstone Oncology initiated with an Outperform at Baird 04/01/20 B. Riley FBR IMV Inc. downgraded to Neutral from Buy at B. Riley FBR 03/18/20 Raymond James IMV Inc. downgraded to Market Perform from Outperform at Raymond James 02/28/20 B. Riley FBR IMV Inc. selloff this weekend is overdone, says B. Riley FBR 02/25/20 H.C. Wainwright IMV's DeCidE1 results 'quite encouraging,' says H.C. Wainwright INFI Infinity Pharmaceuticals $0.89 / +0.0875 (+10.94%)
11/18/19 B. Riley FBR Infinity Pharmaceuticals resumed with a Buy at B. Riley FBR 06/27/19 Fly Intel: Top five analyst initiations 06/27/19 Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform 06/26/19 Oppenheimer Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer 03/25/20 Raymond James Jounce upgraded to Strong Buy ahead of cancer data at Raymond James 03/25/20 Raymond James Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James 04/02/20 H.C. Wainwright Momenta's Vivacity-MG still on track despite COVID-19, says H.C. Wainwright 04/02/20 Piper Sandler Piper Sandler says enrollment delays already priced into Momenta shares 03/12/20 Fly Intel: Top five analyst initiations 03/12/20 Goldman Sachs Momenta initiated with a Neutral at Goldman Sachs 03/31/20 Cantor Fitzgerald MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive' 02/11/20 Credit Suisse MyoKardia price target raised to $82 from $77 at Credit Suisse 02/07/20 JPMorgan MyoKardia shares can reach $100-$115 on positive data, says JPMorgan 01/27/20 Guggenheim Guggenheim has high conviction in MyoKardia trial after cardiologist survey 03/26/20 Piper Sandler uniQure trial delay 'comes as no surprise,' says Piper Sandler 01/23/20 Cantor Fitzgerald Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate 12/10/19 Mizuho uniQure price target raised to $90 from $67 at Mizuho 12/09/19 Piper Sandler Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH VYGR Voyager Therapeutics 03/30/20 Nomura Instinet Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet 03/19/20 Fly Intel: Top five analyst initiations 03/19/20 Benchmark Benchmark starts Voyager Therapeutics at Buy with $18 price target 03/19/20 Benchmark Voyager Therapeutics initiated with a Buy at Benchmark
Recommendations
Wells Fargo analyst Jim…
Wells Fargo analyst Jim Birchenough lowered the firm's price target on Celyad to $20 from $44 following review of Q4 results for the company's novel CAR-T pipeline and platform. The analyst keeps an Overweight rating on the shares.
Show Hide Related Items >> <<
03/25/20 H.C. Wainwright Celyad price target lowered to $37 from $43 at H.C. Wainwright 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust
Recommendations
H.C. Wainwright analyst…
H.C. Wainwright analyst Edward White lowered the firm's price target on Celyad to $37 from $43 and keeps a Buy rating on the shares. White said that the company's reported 2019 revenue estimate was in-line with his estimate while EPS was above his estimate. The analyst noted that preliminary results from the THINK trial's expansion cohort are now expected in the second half of the year, compared to the prior timing of late first half, due to enrollment delays caused by the COVID-19 pandemic. White added that despite the COVID-19 related delays, he continues to believe the company could decide by year end 2020 on whether to pursue the THINK or DEPLETHINK for CYAD-01.
Show Hide Related Items >> <<
07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update
Hot Stocks
Celyad (CYAD) announced…
Celyad (CYAD) announced that Stephen Rubino, Ph.D., has been appointed Chief Business Officer. Dr. Rubino has more than 25 years of strong commercial and strategic development experience in the pharmaceutical and biotechnology industry, including 17 years at Novartis (NVS). He will serve on the executive leadership team and will lead business and corporate development for Celyad.
Show Hide Related Items >> <<
07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 02/26/20 Bernstein Regeneron upgraded to Outperform from Market Perform at Bernstein 02/26/20 Canaccord Regeneron competitive concerns decrease, Canaccord upgrades to Buy 02/26/20 Credit Suisse Regeneron price target raised to $510 from $420 at Credit Suisse 02/26/20 Baird Regeneron downgraded to Neutral from Outperform at Baird
Conference/Events
9th Annual Global…
9th Annual Global Healthcare Conference will be held in New York on February 25-27.
Show Hide Related Items >> <<
02/18/20 Cowen AbbVie price target raised to $105 from $98 at Cowen 02/14/20 Piper Sandler Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant 02/11/20 SunTrust Allergan price target raised to $202 from $194 at SunTrust 02/10/20 Mizuho AbbVie price target raised to $104 from $96 at Mizuho 02/19/20 Fly Intel: Top five analyst initiations 02/19/20 Mizuho Mizuho starts BridgeBio with Buy rating, $51 price target 02/18/20 Mizuho BridgeBio initiated with a Buy at Mizuho 01/07/20 Raymond James BridgeBio price target raised to $40 from $36 at Raymond James 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 02/20/20 Piper Sandler Deciphera 20% selloff brings 'great entry point,' says Piper Sandler 01/24/20 SVB Leerink Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink 01/22/20 Piper Sandler Piper Sandler says 'incrementally positive' on Deciphera FULC Fulcrum Therapeutics 12/24/19 H.C. Wainwright Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright 10/03/19 H.C. Wainwright Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright 08/12/19 Morgan Stanley Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley 08/12/19 BofA Fulcrum Therapeutics initiated with a Buy at BofA/Merrill 02/21/20 Fly Intel: Top five analyst initiations 02/21/20 Guggenheim Guggenheim starts Guardant Health at Buy with addressable market seen expanding 02/21/20 Guggenheim Guardant Health initiated with a Buy at Guggenheim 01/09/20 JPMorgan Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools 02/24/20 Fly Intel: Top five analyst initiations 02/24/20 SVB Leerink Immunovant initiated with an Outperform at SVB Leerink 02/05/20 Fly Intel: Top five analyst initiations 02/05/20 Nomura Instinet Immunovant initiated with a Buy at Nomura Instinet 01/13/20 William Blair Inogen's softer than expected DTC demand a surprise, says William Blair 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 09/12/19 Piper Sandler Piper confident in Inogen's double-digit growth potential for 2020 10/24/19 Lake Street Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34 10/24/19 Lake Street LeMaitre upgraded to Buy from Hold at Lake Street 10/24/19 First Analysis LeMaitre downgraded to Outperform from Strong Buy at First Analysis 10/14/19 First Analysis LeMaitre upgraded to Strong Buy from Outperform at First Analysis 01/13/20 Morgan Stanley Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth 01/13/20 Morgan Stanley Nuance upgraded to Overweight from Equal Weight at Morgan Stanley 10/02/19 Evercore ISI Cerence initiated with an Outperform at Evercore ISI 10/01/19 Raymond James Cerence initiated with a Strong Buy at Raymond James 10/24/19 H.C. Wainwright Neovasc initiated with a Buy at H.C. Wainwright 03/22/19 Canaccord Neovasc court win in Germany removes overhang, says Canaccord 01/10/20 SunTrust Ultragenyx price target raised to $80 from $75 at SunTrust 01/10/20 Piper Sandler Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler 12/18/19 Piper Sandler Piper remains buyer of Ultragenyx after Royalty Pharma deal 11/27/19 Cowen Ultragenyx weakness a buying opportunity, says Cowen 01/23/20 Cantor Fitzgerald Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate 12/10/19 Mizuho uniQure price target raised to $90 from $67 at Mizuho 12/09/19 Piper Sandler Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH 12/09/19 H.C. Wainwright uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright 02/21/20 Cantor Fitzgerald Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald 02/18/20 Mizuho Selecta Biosciences price target raised to $7 from $4 at Mizuho 01/29/20 Fly Intel: Top five analyst initiations 01/29/20 Cantor Fitzgerald Cantor starts 'under the radar' Selecta Biosciences with Overweight rating 10/09/19 H.C. Wainwright Vericel initiated with a Buy rating at H.C. Wainwright 08/26/19 Credit Suisse Organogenesis reinstated with an Outperform at Credit Suisse 08/14/19 Oppenheimer MediWound price target lowered to $7 from $15 at Oppenheimer 05/07/19 Oppenheimer Vericel price target raised to $32 from $23 at Oppenheimer 11/06/19 SVB Leerink Radius Health price target lowered to $35 from $49 at SVB Leerink 08/29/19 Citi Radius Health upgraded to Buy from Neutral at Citi 05/30/19 Citi Radius Health assumed with a Neutral at Citi 05/29/19 Goldman Sachs Radius Health upgraded to Buy from Neutral at Goldman Sachs $180.00 / -17.03 (-8.64%)
02/26/20 Cowen Insulet weakness a buying opportunity, says Cowen 02/26/20 Raymond James Insulet price target lowered to $205 from $213 at Raymond James 02/26/20 Piper Sandler Insulet should be bought on selloff from guidance, says Piper Sandler 02/19/20 Piper Sandler New partnerships expected, but positive, for Insulet, says Piper Sandler 07/12/19 WBB Securities RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities 03/12/19 Fly Intel: Top five analyst upgrades 03/12/19 WBB Securities RedHill Biopharma upgraded to Buy from Hold at WBB Securities 02/27/19 H.C. Wainwright RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright 11/04/19 H.C. Wainwright TCR2 Therapeutics initiated with a Buy at H.C. Wainwright 05/31/19 Roth Capital TCR2 Therapeutics initiated with a Neutral at Roth Capital 03/11/19 Fly Intel: Top five analyst initiations 03/11/19 SVB Leerink TCR2 Therapeutics initiated with an Outperform at SVB Leerink 01/10/20 SVB Leerink Organogenesis initiated with an Outperform at SVB Leerink 05/02/19 Credit Suisse Organogenesis initiated with an Outperform at Credit Suisse 04/17/19 Fly Intel: Top five analyst initiations OSMT Osmotica Pharmaceuticals 01/22/20 Wells Fargo Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo 08/12/19 Jefferies Osmotica shares discounting late-stage pipeline, says Jefferies 06/11/19 Barclays Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays 03/28/19 Wells Fargo Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results MLND Millendo Therapeutics 01/10/20 Roth Capital Millendo Therapeutics initiated with a Buy at Roth Capital 09/16/19 Jefferies Millendo Therapeutics assumed with a Buy at Jefferies 07/19/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 07/18/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 02/20/20 Fly Intel: Top five analyst initiations 02/19/20 Evercore ISI Intra-Cellular initiated with an Outperform at Evercore ISI 02/18/20 Cantor Fitzgerald Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald 01/31/20 JPMorgan Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan 07/19/19 Raymond James InflaRx should not proceed with IFX-1 in HS, says Raymond James 06/06/19 Raymond James ChemoCentryx price target lowered to $17 from $24 at Raymond James 06/05/19 InflaRx downgraded to Market Perform on HS study results at Raymond James 06/05/19 Piper Sandler Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure STSA Satsuma Pharmaceuticals 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 10/08/19 SVB Leerink Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink 10/08/19 Credit Suisse Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse MIRM Mirum Pharmaceuticals 12/17/19 Citi Mirum Pharmaceuticals price target raised to $30 from $21 at Citi 12/16/19 Roth Capital Mirum update shortens development timeframe by two years, says Roth Capital 08/12/19 Fly Intel: Top five analyst initiations 08/12/19 Raymond James Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Over a quarter ago
Conference/Events
9th Annual Global…
9th Annual Global Healthcare Conference will be held in New York on February 25-27.
Show Hide Related Items >> <<
02/18/20 Cowen AbbVie price target raised to $105 from $98 at Cowen 02/14/20 Piper Sandler Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant 02/11/20 SunTrust Allergan price target raised to $202 from $194 at SunTrust 02/10/20 Mizuho AbbVie price target raised to $104 from $96 at Mizuho 02/19/20 Fly Intel: Top five analyst initiations 02/19/20 Mizuho Mizuho starts BridgeBio with Buy rating, $51 price target 02/18/20 Mizuho BridgeBio initiated with a Buy at Mizuho 01/07/20 Raymond James BridgeBio price target raised to $40 from $36 at Raymond James 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 02/20/20 Piper Sandler Deciphera 20% selloff brings 'great entry point,' says Piper Sandler 01/24/20 SVB Leerink Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink 01/22/20 Piper Sandler Piper Sandler says 'incrementally positive' on Deciphera FULC Fulcrum Therapeutics 12/24/19 H.C. Wainwright Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright 10/03/19 H.C. Wainwright Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright 08/12/19 Morgan Stanley Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley 08/12/19 BofA Fulcrum Therapeutics initiated with a Buy at BofA/Merrill 02/21/20 Fly Intel: Top five analyst initiations 02/21/20 Guggenheim Guggenheim starts Guardant Health at Buy with addressable market seen expanding 02/21/20 Guggenheim Guardant Health initiated with a Buy at Guggenheim 01/09/20 JPMorgan Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools 02/24/20 Fly Intel: Top five analyst initiations 02/24/20 SVB Leerink Immunovant initiated with an Outperform at SVB Leerink 02/05/20 Fly Intel: Top five analyst initiations 02/05/20 Nomura Instinet Immunovant initiated with a Buy at Nomura Instinet 01/13/20 William Blair Inogen's softer than expected DTC demand a surprise, says William Blair 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 09/12/19 Piper Sandler Piper confident in Inogen's double-digit growth potential for 2020 10/24/19 Lake Street Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34 10/24/19 Lake Street LeMaitre upgraded to Buy from Hold at Lake Street 10/24/19 First Analysis LeMaitre downgraded to Outperform from Strong Buy at First Analysis 10/14/19 First Analysis LeMaitre upgraded to Strong Buy from Outperform at First Analysis 01/13/20 Morgan Stanley Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth 01/13/20 Morgan Stanley Nuance upgraded to Overweight from Equal Weight at Morgan Stanley 10/02/19 Evercore ISI Cerence initiated with an Outperform at Evercore ISI 10/01/19 Raymond James Cerence initiated with a Strong Buy at Raymond James 10/24/19 H.C. Wainwright Neovasc initiated with a Buy at H.C. Wainwright 03/22/19 Canaccord Neovasc court win in Germany removes overhang, says Canaccord 01/10/20 SunTrust Ultragenyx price target raised to $80 from $75 at SunTrust 01/10/20 Piper Sandler Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler 12/18/19 Piper Sandler Piper remains buyer of Ultragenyx after Royalty Pharma deal 11/27/19 Cowen Ultragenyx weakness a buying opportunity, says Cowen 01/23/20 Cantor Fitzgerald Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate 12/10/19 Mizuho uniQure price target raised to $90 from $67 at Mizuho 12/09/19 Piper Sandler Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH 12/09/19 H.C. Wainwright uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright 02/21/20 Cantor Fitzgerald Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald 02/18/20 Mizuho Selecta Biosciences price target raised to $7 from $4 at Mizuho 01/29/20 Fly Intel: Top five analyst initiations 01/29/20 Cantor Fitzgerald Cantor starts 'under the radar' Selecta Biosciences with Overweight rating 10/09/19 H.C. Wainwright Vericel initiated with a Buy rating at H.C. Wainwright 08/26/19 Credit Suisse Organogenesis reinstated with an Outperform at Credit Suisse 08/14/19 Oppenheimer MediWound price target lowered to $7 from $15 at Oppenheimer 05/07/19 Oppenheimer Vericel price target raised to $32 from $23 at Oppenheimer 11/06/19 SVB Leerink Radius Health price target lowered to $35 from $49 at SVB Leerink 08/29/19 Citi Radius Health upgraded to Buy from Neutral at Citi 05/30/19 Citi Radius Health assumed with a Neutral at Citi 05/29/19 Goldman Sachs Radius Health upgraded to Buy from Neutral at Goldman Sachs $197.03 / -10.46 (-5.04%)
02/19/20 Piper Sandler New partnerships expected, but positive, for Insulet, says Piper Sandler 02/13/20 Piper Sandler Insulet medical device correction will not impact growth, says Piper Sandler 02/06/20 Raymond James Insulet price target raised to $213 from $158 at Raymond James 01/07/20 Cowen Cowen sees minimal Q4 earnings risk for diabetes device stocks 07/12/19 WBB Securities RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities 03/12/19 Fly Intel: Top five analyst upgrades 03/12/19 WBB Securities RedHill Biopharma upgraded to Buy from Hold at WBB Securities 02/27/19 H.C. Wainwright RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright 11/04/19 H.C. Wainwright TCR2 Therapeutics initiated with a Buy at H.C. Wainwright 05/31/19 Roth Capital TCR2 Therapeutics initiated with a Neutral at Roth Capital 03/11/19 Fly Intel: Top five analyst initiations 03/11/19 SVB Leerink TCR2 Therapeutics initiated with an Outperform at SVB Leerink 01/10/20 SVB Leerink Organogenesis initiated with an Outperform at SVB Leerink 05/02/19 Credit Suisse Organogenesis initiated with an Outperform at Credit Suisse 04/17/19 Fly Intel: Top five analyst initiations OSMT Osmotica Pharmaceuticals 01/22/20 Wells Fargo Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo 08/12/19 Jefferies Osmotica shares discounting late-stage pipeline, says Jefferies 06/11/19 Barclays Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays 03/28/19 Wells Fargo Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results MLND Millendo Therapeutics 01/10/20 Roth Capital Millendo Therapeutics initiated with a Buy at Roth Capital 09/16/19 Jefferies Millendo Therapeutics assumed with a Buy at Jefferies 07/19/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 07/18/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 02/20/20 Fly Intel: Top five analyst initiations 02/19/20 Evercore ISI Intra-Cellular initiated with an Outperform at Evercore ISI 02/18/20 Cantor Fitzgerald Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald 01/31/20 JPMorgan Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan 07/19/19 Raymond James InflaRx should not proceed with IFX-1 in HS, says Raymond James 06/06/19 Raymond James ChemoCentryx price target lowered to $17 from $24 at Raymond James 06/05/19 InflaRx downgraded to Market Perform on HS study results at Raymond James 06/05/19 Piper Sandler Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure STSA Satsuma Pharmaceuticals 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 10/08/19 SVB Leerink Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink 10/08/19 Credit Suisse Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse MIRM Mirum Pharmaceuticals 12/17/19 Citi Mirum Pharmaceuticals price target raised to $30 from $21 at Citi 12/16/19 Roth Capital Mirum update shortens development timeframe by two years, says Roth Capital 08/12/19 Fly Intel: Top five analyst initiations 08/12/19 Raymond James Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Conference/Events
9th Annual Global…
9th Annual Global Healthcare Conference will be held in New York on February 25-27.
Show Hide Related Items >> <<
02/18/20 Cowen AbbVie price target raised to $105 from $98 at Cowen 02/14/20 Piper Sandler Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant 02/11/20 SunTrust Allergan price target raised to $202 from $194 at SunTrust 02/10/20 Mizuho AbbVie price target raised to $104 from $96 at Mizuho 02/19/20 Fly Intel: Top five analyst initiations 02/19/20 Mizuho Mizuho starts BridgeBio with Buy rating, $51 price target 02/18/20 Mizuho BridgeBio initiated with a Buy at Mizuho 01/07/20 Raymond James BridgeBio price target raised to $40 from $36 at Raymond James 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 02/20/20 Piper Sandler Deciphera 20% selloff brings 'great entry point,' says Piper Sandler 01/24/20 SVB Leerink Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink 01/22/20 Piper Sandler Piper Sandler says 'incrementally positive' on Deciphera FULC Fulcrum Therapeutics 12/24/19 H.C. Wainwright Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright 10/03/19 H.C. Wainwright Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright 08/12/19 Morgan Stanley Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley 08/12/19 BofA Fulcrum Therapeutics initiated with a Buy at BofA/Merrill 02/21/20 Fly Intel: Top five analyst initiations 02/21/20 Guggenheim Guggenheim starts Guardant Health at Buy with addressable market seen expanding 02/21/20 Guggenheim Guardant Health initiated with a Buy at Guggenheim 01/09/20 JPMorgan Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools 02/24/20 Fly Intel: Top five analyst initiations 02/24/20 SVB Leerink Immunovant initiated with an Outperform at SVB Leerink 02/05/20 Fly Intel: Top five analyst initiations 02/05/20 Nomura Instinet Immunovant initiated with a Buy at Nomura Instinet 01/13/20 William Blair Inogen's softer than expected DTC demand a surprise, says William Blair 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 11/06/19 Needham Inogen upgraded to Buy from Hold at Needham 09/12/19 Piper Sandler Piper confident in Inogen's double-digit growth potential for 2020 10/24/19 Lake Street Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34 10/24/19 Lake Street LeMaitre upgraded to Buy from Hold at Lake Street 10/24/19 First Analysis LeMaitre downgraded to Outperform from Strong Buy at First Analysis 10/14/19 First Analysis LeMaitre upgraded to Strong Buy from Outperform at First Analysis 01/13/20 Morgan Stanley Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth 01/13/20 Morgan Stanley Nuance upgraded to Overweight from Equal Weight at Morgan Stanley 10/02/19 Evercore ISI Cerence initiated with an Outperform at Evercore ISI 10/01/19 Raymond James Cerence initiated with a Strong Buy at Raymond James 10/24/19 H.C. Wainwright Neovasc initiated with a Buy at H.C. Wainwright 03/22/19 Canaccord Neovasc court win in Germany removes overhang, says Canaccord 01/10/20 SunTrust Ultragenyx price target raised to $80 from $75 at SunTrust 01/10/20 Piper Sandler Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler 12/18/19 Piper Sandler Piper remains buyer of Ultragenyx after Royalty Pharma deal 11/27/19 Cowen Ultragenyx weakness a buying opportunity, says Cowen 01/23/20 Cantor Fitzgerald Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate 12/10/19 Mizuho uniQure price target raised to $90 from $67 at Mizuho 12/09/19 Piper Sandler Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH 12/09/19 H.C. Wainwright uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright 02/21/20 Cantor Fitzgerald Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald 02/18/20 Mizuho Selecta Biosciences price target raised to $7 from $4 at Mizuho 01/29/20 Fly Intel: Top five analyst initiations 01/29/20 Cantor Fitzgerald Cantor starts 'under the radar' Selecta Biosciences with Overweight rating 10/09/19 H.C. Wainwright Vericel initiated with a Buy rating at H.C. Wainwright 08/26/19 Credit Suisse Organogenesis reinstated with an Outperform at Credit Suisse 08/14/19 Oppenheimer MediWound price target lowered to $7 from $15 at Oppenheimer 05/07/19 Oppenheimer Vericel price target raised to $32 from $23 at Oppenheimer 11/06/19 SVB Leerink Radius Health price target lowered to $35 from $49 at SVB Leerink 08/29/19 Citi Radius Health upgraded to Buy from Neutral at Citi 05/30/19 Citi Radius Health assumed with a Neutral at Citi 05/29/19 Goldman Sachs Radius Health upgraded to Buy from Neutral at Goldman Sachs 02/19/20 Piper Sandler New partnerships expected, but positive, for Insulet, says Piper Sandler 02/13/20 Piper Sandler Insulet medical device correction will not impact growth, says Piper Sandler 02/06/20 Raymond James Insulet price target raised to $213 from $158 at Raymond James 01/07/20 Cowen Cowen sees minimal Q4 earnings risk for diabetes device stocks 07/12/19 WBB Securities RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities 03/12/19 Fly Intel: Top five analyst upgrades 03/12/19 WBB Securities RedHill Biopharma upgraded to Buy from Hold at WBB Securities 02/27/19 H.C. Wainwright RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright 11/04/19 H.C. Wainwright TCR2 Therapeutics initiated with a Buy at H.C. Wainwright 05/31/19 Roth Capital TCR2 Therapeutics initiated with a Neutral at Roth Capital 03/11/19 Fly Intel: Top five analyst initiations 03/11/19 SVB Leerink TCR2 Therapeutics initiated with an Outperform at SVB Leerink 01/10/20 SVB Leerink Organogenesis initiated with an Outperform at SVB Leerink 05/02/19 Credit Suisse Organogenesis initiated with an Outperform at Credit Suisse 04/17/19 Fly Intel: Top five analyst initiations OSMT Osmotica Pharmaceuticals 01/22/20 Wells Fargo Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo 08/12/19 Jefferies Osmotica shares discounting late-stage pipeline, says Jefferies 06/11/19 Barclays Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays 03/28/19 Wells Fargo Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results MLND Millendo Therapeutics 01/10/20 Roth Capital Millendo Therapeutics initiated with a Buy at Roth Capital 09/16/19 Jefferies Millendo Therapeutics assumed with a Buy at Jefferies 07/19/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 07/18/19 Wedbush Millendo Therapeutics initiated with an Outperform at Wedbush 02/20/20 Fly Intel: Top five analyst initiations 02/19/20 Evercore ISI Intra-Cellular initiated with an Outperform at Evercore ISI 02/18/20 Cantor Fitzgerald Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald 01/31/20 JPMorgan Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan 07/19/19 Raymond James InflaRx should not proceed with IFX-1 in HS, says Raymond James 06/06/19 Raymond James ChemoCentryx price target lowered to $17 from $24 at Raymond James 06/05/19 InflaRx downgraded to Market Perform on HS study results at Raymond James 06/05/19 Piper Sandler Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure STSA Satsuma Pharmaceuticals 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 02/05/20 Mizuho Satsuma Pharmaceuticals initiated with a Buy at Mizuho 10/08/19 SVB Leerink Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink 10/08/19 Credit Suisse Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse MIRM Mirum Pharmaceuticals 12/17/19 Citi Mirum Pharmaceuticals price target raised to $30 from $21 at Citi 12/16/19 Roth Capital Mirum update shortens development timeframe by two years, says Roth Capital 08/12/19 Fly Intel: Top five analyst initiations 08/12/19 Raymond James Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Hot Stocks
Celyad announced the…
Celyad announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia patient enrolled in the Phase 1 CYCLE-1 trial.
Show Hide Related Items >> <<
07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update
Conference/Events
HealthCONx Conference…
HealthCONx Conference 2019 will be held in Boston on December 3-5.
Show Hide Related Items >> <<
04/29/19 UBS Molecular Templates initiated with a Buy at UBS 12/10/18 Oppenheimer Molecular Templates initiated with an Outperform at Oppenheimer ALNA Allena Pharmaceuticals 11/08/19 B. Riley FBR Allena Pharmaceuticals selloff yesterday overdone, says B. Riley FBR 11/07/19 Roth Capital Allena's high placebo result in URIROX-1 a 'red herring,' says Roth Capital 11/07/19 Baird Allena Pharmaceuticals selloff today a buying opportunity, says Baird 09/06/19 Credit Suisse Allena Pharmaceuticals price target lowered to $7 from $26 at Credit Suisse MDGL Madrigal Pharmaceuticals 12/02/19 Citi Madrigal Pharmaceuticals price target lowered to $166 from $173 at Citi 09/17/19 Citi Madrigal Pharmaceuticals price target lowered to $173 from $186 at Citi 06/25/19 Stifel Madrigal Pharmaceuticals initiated with a Hold at Stifel 06/10/19 B. Riley FBR Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR 07/30/19 Fly Intel: Top five analyst initiations 07/30/19 Citi Philips initiated with a Buy at Citi 04/16/19 BTIG Masimo downgraded to Neutral from Buy at BTIG 12/03/19 Piper Sandler uniQure a name 'investors need to own,' says Piper Jaffray 12/03/19 Fly Intel: Top five analyst initiations 12/03/19 Cowen uniQure initiated with an Outperform at Cowen 12/03/19 Goldman Sachs uniQure initiated with a Buy at Goldman Sachs 11/20/19 Cantor Fitzgerald Mustang Bio assumed with an Overweight at Cantor Fitzgerald 08/13/19 H.C. Wainwright Mustang Bio initiated with a Buy at H.C. Wainwright 06/21/19 Cantor Fitzgerald Cantor starts Mustang Bio with Overweight rating, $7 price target 06/20/19 Cantor Fitzgerald Mustang Bio initiated with an Overweight at Cantor Fitzgerald $0.95 / +0.0863 (+10.03%)
11/18/19 H.C. Wainwright Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright 11/14/19 Benchmark Seelos Therapeutics initiated with a Speculative Buy at Benchmark 05/14/19 Roth Capital Seelos Therapeutics initiated with a Buy at Roth Capital 05/10/19 H.C. Wainwright Seelos Therapeutics initiated with a Buy at H.C. Wainwright 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 10/25/19 Cantor Fitzgerald Cantor starts Pfenex at Overweight, sees 'significant value' despite run 10/24/19 Cantor Fitzgerald Pfenex initiated with an Overweight at Cantor Fitzgerald 09/11/19 JMP Securities Pfenex price target raised to $17 from $13 at JMP Securities 04/02/19 Wells Fargo BARDA passing on Pfenex good news for Emergent, says Wells Fargo 10/07/19 Fly Intel: Top five analyst initiations 10/07/19 BTIG Sutro Biopharma initiated with a Buy at BTIG 09/05/19 JMP Securities Sutro Biopharma resumed with an Outperform at JMP Securities 07/18/19 Deutsche Bank Sutro Biopharma initiated with a Buy at Deutsche Bank 11/05/19 Piper Sandler Medtronic filed patent lawsuit against Axonics, says Piper Jaffray 11/04/19 Piper Sandler Axonics doctor checks suggest 'meaningful share capture,' says Piper Jaffray 11/01/19 Piper Sandler Axonics initiated with an Overweight at Piper Jaffray 10/21/19 Barclays Axonics initiated with an Overweight at Barclays NBSE NeuBase Therapeutics 11/20/19 Oppenheimer NeuBase Therapeutics initiated with an Outperform at Oppenheimer 10/29/19 H.C. Wainwright NeuBase Therapeutics initiated with a Buy at H.C. Wainwright 09/24/19 BTIG NeuBase Therapeutics initiated with a Buy at BTIG 12/04/19 Raymond James Zimmer Biomet upgraded to Strong Buy at Raymond James, PT raised to $170 12/04/19 Raymond James Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James 11/06/19 Raymond James Zimmer Biomet price target raised to $160 from $150 at Raymond James 11/06/19 SVB Leerink Zimmer Biomet price target raised to $160 from $155 at SVB Leerink 09/30/19 B. Riley FBR Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR 05/28/19 Craig-Hallum Alimera Sciences initiated with a Buy at Craig-Hallum 09/03/19 Goldman Sachs Insmed initiated with a Buy at Goldman Sachs 08/01/19 Stifel Insmed selloff 'decidedly overdone,' says Stifel 04/09/19 H.C. Wainwright Insmed price target raised to $52 from $43 at H.C. Wainwright 03/26/19 Stifel Pulmonologist call reinforces Stifel view of upside for Insmed ADMS Adamas Pharmaceuticals 11/08/19 JMP Securities Adamas Pharmaceuticals price target lowered to $16 from $57 at JMP Securities 09/30/19 BofA Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill 09/30/19 BofA Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill 09/09/19 Fly Intel: Top five analyst initiations 08/12/19 Baird Axovant upgraded to Outperform at Baird 08/12/19 Baird Axovant upgraded to Outperform from Neutral at Baird 06/21/19 SVB Leerink Axovant initiated with an Outperform at SVB Leerink 06/06/19 JMP Securities Axovant price target raised to $28 after reverse split at JMP Securities 09/04/19 Roth Capital Atreca initiated with a Buy at Roth Capital 07/15/19 Fly Intel: Top five analyst initiations 07/15/19 Cowen Atreca initiated with an Outperform at Cowen 07/15/19 Canaccord Atreca initiated with a Buy at Canaccord 11/19/19 Goldman Sachs Myovant Sciences price target raised to $20 from $18 at Goldman Sachs 11/19/19 JMP Securities JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data 08/28/19 Fly Intel: Top five analyst initiations 08/28/19 Goldman Sachs Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs PIRS Pieris Pharmaceuticals 07/30/19 Baird Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird 07/29/19 William Blair Updates 'very positive' for upcoming Pieris presentation, says William Blair 05/14/19 Baird Pieris Pharmaceuticals initiated with an Outperform at Baird 05/13/19 Baird Pieris Pharmaceuticals initiated with an Outperform at Baird 11/19/19 Morgan Stanley Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley 11/07/19 Fly Intel: Top five analyst downgrades 11/07/19 Morgan Stanley Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley 11/07/19 Morgan Stanley Mylan downgraded to Equal Weight from Overweight at Morgan Stanley RCKT Rocket Pharmaceuticals 11/18/19 Piper Sandler Rocket may be next leading lentiviral vector company, says Piper Jaffray 11/07/19 Piper Sandler Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray 11/05/19 Chardan Rocket Pharmaceuticals initiated with a Buy at Chardan 10/24/19 Piper Sandler Rocket Pharmaceuticals data update 'incrementally positive,' says Piper Jaffray 11/26/19 H.C. Wainwright Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright 11/26/19 Fly Intel: Top five analyst downgrades 11/26/19 Roth Capital CymaBay downgraded to Neutral from Buy at Roth Capital 11/26/19 Raymond James CymaBay double downgraded at Raymond James after seladelpar setback 11/05/19 Piper Sandler Neurocrine price target raised to $116 from $111 at Piper Jaffray 10/04/19 Guggenheim Guggenheim positively biased on Biotech heading into earnings 09/25/19 RBC Capital Neurocrine approval in Huntington's could add upside, says RBC Capital 06/27/19 Goldman Sachs Goldman starts 'potential game-changer' Tricida with Buy, $48 price target 06/26/19 Goldman Sachs Tricida initiated with a Buy at Goldman Sachs 05/24/19 Needham Tricida initiated with a Buy at Needham 04/01/19 Empire Tricida price target raised to $58 from $37 at Empire NTLA Intellia Therapeutics 12/03/19 Raymond James Audentes downgraded to Market Perform from Outperform at Raymond James 11/01/19 Raymond James Intellia Therapeutics upgraded to Outperform at Raymond James 11/01/19 Raymond James Intellia upgraded to Outperform from Market Perform at Raymond James 07/09/19 Fly Intel: Top five analyst initiations 11/18/19 Piper Sandler Alkermes deal strengthens early-stage pipeline, says Piper Jaffray 11/18/19 Stifel Alkermes made 'nice strategic move' in buying Rodin, says Stifel 11/11/19 Morgan Stanley Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley 11/01/19 H.C. Wainwright Alkermes price target lowered to $26 from $28 at H.C. Wainwright
Conference/Events
HealthCONx Conference…
HealthCONx Conference 2019 will be held in Boston on December 3-5.
Show Hide Related Items >> <<
04/29/19 UBS Molecular Templates initiated with a Buy at UBS 12/10/18 Oppenheimer Molecular Templates initiated with an Outperform at Oppenheimer ALNA Allena Pharmaceuticals 11/08/19 B. Riley FBR Allena Pharmaceuticals selloff yesterday overdone, says B. Riley FBR 11/07/19 Roth Capital Allena's high placebo result in URIROX-1 a 'red herring,' says Roth Capital 11/07/19 Baird Allena Pharmaceuticals selloff today a buying opportunity, says Baird 09/06/19 Credit Suisse Allena Pharmaceuticals price target lowered to $7 from $26 at Credit Suisse MDGL Madrigal Pharmaceuticals 12/02/19 Citi Madrigal Pharmaceuticals price target lowered to $166 from $173 at Citi 09/17/19 Citi Madrigal Pharmaceuticals price target lowered to $173 from $186 at Citi 06/25/19 Stifel Madrigal Pharmaceuticals initiated with a Hold at Stifel 06/10/19 B. Riley FBR Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR 07/30/19 Fly Intel: Top five analyst initiations 07/30/19 Citi Philips initiated with a Buy at Citi 04/16/19 BTIG Masimo downgraded to Neutral from Buy at BTIG 12/03/19 Piper Sandler uniQure a name 'investors need to own,' says Piper Jaffray 12/03/19 Fly Intel: Top five analyst initiations 12/03/19 Cowen uniQure initiated with an Outperform at Cowen 12/03/19 Goldman Sachs uniQure initiated with a Buy at Goldman Sachs 11/20/19 Cantor Fitzgerald Mustang Bio assumed with an Overweight at Cantor Fitzgerald 08/13/19 H.C. Wainwright Mustang Bio initiated with a Buy at H.C. Wainwright 06/21/19 Cantor Fitzgerald Cantor starts Mustang Bio with Overweight rating, $7 price target 06/20/19 Cantor Fitzgerald Mustang Bio initiated with an Overweight at Cantor Fitzgerald 11/18/19 H.C. Wainwright Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright 11/14/19 Benchmark Seelos Therapeutics initiated with a Speculative Buy at Benchmark 05/14/19 Roth Capital Seelos Therapeutics initiated with a Buy at Roth Capital 05/10/19 H.C. Wainwright Seelos Therapeutics initiated with a Buy at H.C. Wainwright 07/05/19 H.C. Wainwright Celyad target lowered to $48 on new launch timeline at H.C. Wainwright 07/05/19 Piper Sandler Celyad price target lowered to $25 from $41 at Piper Jaffray 06/17/19 SunTrust Celyad selloff a buying opportunity, says SunTrust 06/17/19 Piper Sandler Piper Jaffray reiterates Overweight on Celyad after EHA update 10/25/19 Cantor Fitzgerald Cantor starts Pfenex at Overweight, sees 'significant value' despite run 10/24/19 Cantor Fitzgerald Pfenex initiated with an Overweight at Cantor Fitzgerald 09/11/19 JMP Securities Pfenex price target raised to $17 from $13 at JMP Securities 04/02/19 Wells Fargo BARDA passing on Pfenex good news for Emergent, says Wells Fargo 10/07/19 Fly Intel: Top five analyst initiations 10/07/19 BTIG Sutro Biopharma initiated with a Buy at BTIG 09/05/19 JMP Securities Sutro Biopharma resumed with an Outperform at JMP Securities 07/18/19 Deutsche Bank Sutro Biopharma initiated with a Buy at Deutsche Bank 11/05/19 Piper Sandler Medtronic filed patent lawsuit against Axonics, says Piper Jaffray 11/04/19 Piper Sandler Axonics doctor checks suggest 'meaningful share capture,' says Piper Jaffray 11/01/19 Piper Sandler Axonics initiated with an Overweight at Piper Jaffray 10/21/19 Barclays Axonics initiated with an Overweight at Barclays NBSE NeuBase Therapeutics 11/20/19 Oppenheimer NeuBase Therapeutics initiated with an Outperform at Oppenheimer 10/29/19 H.C. Wainwright NeuBase Therapeutics initiated with a Buy at H.C. Wainwright 09/24/19 BTIG NeuBase Therapeutics initiated with a Buy at BTIG 12/04/19 Raymond James Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James 11/06/19 Raymond James Zimmer Biomet price target raised to $160 from $150 at Raymond James 11/06/19 SVB Leerink Zimmer Biomet price target raised to $160 from $155 at SVB Leerink 11/06/19 RBC Capital Zimmer Biomet price target raised to $155 from $145 at RBC Capital 09/30/19 B. Riley FBR Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR 05/28/19 Craig-Hallum Alimera Sciences initiated with a Buy at Craig-Hallum 09/03/19 Goldman Sachs Insmed initiated with a Buy at Goldman Sachs 08/01/19 Stifel Insmed selloff 'decidedly overdone,' says Stifel 04/09/19 H.C. Wainwright Insmed price target raised to $52 from $43 at H.C. Wainwright 03/26/19 Stifel Pulmonologist call reinforces Stifel view of upside for Insmed ADMS Adamas Pharmaceuticals 11/08/19 JMP Securities Adamas Pharmaceuticals price target lowered to $16 from $57 at JMP Securities 09/30/19 BofA Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill 09/30/19 BofA Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill 09/09/19 Fly Intel: Top five analyst initiations 08/12/19 Baird Axovant upgraded to Outperform at Baird 08/12/19 Baird Axovant upgraded to Outperform from Neutral at Baird 06/21/19 SVB Leerink Axovant initiated with an Outperform at SVB Leerink 06/06/19 JMP Securities Axovant price target raised to $28 after reverse split at JMP Securities $13.29 / +3.185 (+31.53%)
09/04/19 Roth Capital Atreca initiated with a Buy at Roth Capital 07/15/19 Fly Intel: Top five analyst initiations 07/15/19 Cowen Atreca initiated with an Outperform at Cowen 07/15/19 Canaccord Atreca initiated with a Buy at Canaccord 11/19/19 Goldman Sachs Myovant Sciences price target raised to $20 from $18 at Goldman Sachs 11/19/19 JMP Securities JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data 08/28/19 Fly Intel: Top five analyst initiations 08/28/19 Goldman Sachs Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs PIRS Pieris Pharmaceuticals 07/30/19 Baird Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird 07/29/19 William Blair Updates 'very positive' for upcoming Pieris presentation, says William Blair 05/14/19 Baird Pieris Pharmaceuticals initiated with an Outperform at Baird 05/13/19 Baird Pieris Pharmaceuticals initiated with an Outperform at Baird 11/19/19 Morgan Stanley Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley 11/07/19 Fly Intel: Top five analyst downgrades 11/07/19 Morgan Stanley Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley 11/07/19 Morgan Stanley Mylan downgraded to Equal Weight from Overweight at Morgan Stanley RCKT Rocket Pharmaceuticals 11/18/19 Piper Sandler Rocket may be next leading lentiviral vector company, says Piper Jaffray 11/07/19 Piper Sandler Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray 11/05/19 Chardan Rocket Pharmaceuticals initiated with a Buy at Chardan 10/24/19 Piper Sandler Rocket Pharmaceuticals data update 'incrementally positive,' says Piper Jaffray 11/26/19 H.C. Wainwright Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright 11/26/19 Fly Intel: Top five analyst downgrades 11/26/19 Roth Capital CymaBay downgraded to Neutral from Buy at Roth Capital 11/26/19 Raymond James CymaBay double downgraded at Raymond James after seladelpar setback 11/05/19 Piper Sandler Neurocrine price target raised to $116 from $111 at Piper Jaffray 10/04/19 Guggenheim Guggenheim positively biased on Biotech heading into earnings 09/25/19 RBC Capital Neurocrine approval in Huntington's could add upside, says RBC Capital 06/27/19 Goldman Sachs Goldman starts 'potential game-changer' Tricida with Buy, $48 price target 06/26/19 Goldman Sachs Tricida initiated with a Buy at Goldman Sachs 05/24/19 Needham Tricida initiated with a Buy at Needham 04/01/19 Empire Tricida price target raised to $58 from $37 at Empire NTLA Intellia Therapeutics 12/03/19 Raymond James Audentes downgraded to Market Perform from Outperform at Raymond James 11/01/19 Raymond James Intellia Therapeutics upgraded to Outperform at Raymond James 11/01/19 Raymond James Intellia upgraded to Outperform from Market Perform at Raymond James 07/09/19 Fly Intel: Top five analyst initiations 11/18/19 Piper Sandler Alkermes deal strengthens early-stage pipeline, says Piper Jaffray 11/18/19 Stifel Alkermes made 'nice strategic move' in buying Rodin, says Stifel 11/11/19 Morgan Stanley Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley 11/01/19 H.C. Wainwright Alkermes price target lowered to $26 from $28 at H.C. Wainwright